Product Description
Amgen is developing FPT-155 as a treatment for advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04074759)
Mechanisms of Action: CD80 Cleaver
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04074759 |
FPT155-001 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2021-08-10 |
50% |
2025-01-24 |
|
ACTRN12618001955202 |
ACTRN12618001955202 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2021-04-29 |
2024-08-29 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/11/2020 |
News Article |
Five Prime Announces Proposed Public Offering of Common Stock |
|
11/12/2020 |
News Article |
Five Prime Announces Pricing of Upsized Public Offering of Common Stock |
|
11/03/2020 |
News Article |
Five Prime Therapeutics Reports Third Quarter 2020 Results |
|
08/06/2020 |
News Article |
Five Prime Therapeutics Reports Second Quarter 2020 Results |